Letrozole (Femara)
Prescription aromatase inhibitor for breast cancer that lowers estrogen; bodybuilders also use it, and it is banned in competitive sport.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Related comparisons
Anastrozol vs Letrozol vs ExemestaneDETAILED OVERVIEW
What is Letrozole (Femara)?
Letrozole (Femara) is a prescription medicine, a so-called aromatase inhibitor: it blocks the enzyme that makes estrogen, the female sex hormone, from testosterone. Since 1997 it has been approved to treat estrogen-sensitive breast cancer in women after menopause. Bodybuilders use it alongside muscle-building steroids to keep estrogen down and to reverse enlarged breast tissue in men; this is not its approved use.
It is stronger than anastrozole and can suppress estrogen almost completely, so levels easily drop too low, which can cause a collapse in sex drive, erection problems, fatigue and low mood. Joint and muscle pain, hot flashes, headache and dizziness are also common. It worsens cholesterol values (the good HDL falls, the bad LDL rises), and with long-term use it causes bone loss, which raises the risk of fractures. It must not be used in pregnancy, because it can cause severe harm to the fetus and miscarriage. WADA bans it both in and out of competition.
Mechanism
Non-steroidal aromatase inhibitor; estrogen can fall by up to about 99%
Half-life
~42 hours
Onset
E2 reduction measurable 24-48 h, plateau 4-6 days
Legal status
FDA + EMA Rx, HU + PL approved, WADA S4.1 banned
No anecdote collected yet.
Data console
Lab data
Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A . A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.. N Engl J Med.
Bhatnagar AS . The discovery and mechanism of action of letrozole.. Breast Cancer Res Treat.
Jin H, Tu D, Zhao N, Shepherd LE, Goss PE . Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.. J Clin Oncol.
Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE . Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.. J Clin Oncol.
Safety
Side effects, stop signs, contraindications
Side effects · 7
- Over-suppressed (crashed) estradiol: letrozole is more potent than anastrozole (~99% E2 suppression), so it easily drives E2 into symptomatic hypoestrogenism, causing low libido, erectile dysfunction, fatigue and low mood.
- Joint and muscle pain (arthralgia, myalgia): a hallmark of estrogen deprivation, with wrist, knee and hand symptoms and joint stiffness; the most common complaint in clinical trials.
- Worsening lipid profile: with sustained use HDL falls (up to ~30%) and LDL rises (~15-25%), shifting the profile toward unfavourable cardiovascular risk, especially on an aromatizing steroid stack.
- Bone loss and osteoporosis: estrogen is key to maintaining bone density, so prolonged letrozole use lowers BMD and raises the risk of osteoporosis and fractures (FDA Femara label); chronic use warrants DEXA monitoring.
- Hot flushes and increased sweating: a vasomotor symptom of estrogen deficiency and one of the most common clinically documented side effects of letrozole.
- Mood disturbance and fatigue: low estrogen can cause depressed mood, irritability, sleep disturbance and marked tiredness.
- Headache, dizziness and nausea: common, usually mild-to-moderate symptoms during treatment, more so at the higher (2.5 mg/day) gyno-reversal dose.
Contraindications · 7
- Pregnancy and breastfeeding: Pregnancy Category X, blocking estrogen synthesis can cause severe fetal harm and miscarriage, so it is absolutely contraindicated in pregnant women.
- Premenopausal women (endocrine status): due to reflex gonadotropin rise and ovarian dysfunction, it is not indicated for premenopausal female use without proper endocrine supervision.
- Severe hepatic or renal impairment: because of hepatic CYP metabolism and renal excretion, clearance is reduced in severe liver or kidney disease, so use is contraindicated or requires close supervision.
- Pre-existing osteoporosis or low bone density: letrozole further lowers BMD, so it should be avoided with established osteoporosis or fracture risk, or used only with bone protection and DEXA monitoring.
- Already low or crashed estradiol: if E2 is already low or symptomatic hypoestrogenism is present, starting or continuing letrozole is inadvisable – do not start without a baseline E2 (sensitive LC-MS/MS) measurement, especially in AI-naive users.
- Concurrent tamoxifen (Nolvadex): due to a pharmacokinetic interaction tamoxifen lowers letrozole plasma levels, so co-administration is not recommended (and in AAS-PCT it also increases the risk of crashing E2).
- Marked untreated adverse lipid profile or cardiovascular disease: because of the HDL-lowering effect it warrants caution or contraindication with existing dyslipidaemia or heart disease without lipid-panel monitoring.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A
The discovery and mechanism of action of letrozole.
Bhatnagar AS
Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.
Jin H, Tu D, Zhao N, Shepherd LE, Goss PE
Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE
Telegram
Have a question about Letrozole (Femara)?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.


